This biotech growth stock is hammering the AstraZeneca share price. Here’s what you need to know

The AstraZeneca share price is climbing. But this biotech firm is collaborating with the pharmaceuticals giant, and its shares have multi-bagged.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Pharmaceuticals stocks like AstraZeneca (LSE: AZN) are doing well in 2020, for obvious reasons. The AstraZeneca share price is up 9.5% this year, while the FTSE 100 is down 20%. Some biotechnology stocks are doing even better, and  Silence Therapeutics (LSE: SLN) is one of them, with a share price gain of 35%.

Silence has a proprietary technology platform for drug development based on RNA interference. That provides researchers with the ability to develop treatments to selectively inhibit gene expression. I don’t have the expertise to know what’s likely to come from it. But anything that provides the ability to selectively target specific genes responsible for diseases just has to be a good thing.

The company isn’t profitable yet, and that does make it very hard to place a valuation on its shares. I’d expect volatility too, and a comparison with the AstraZeneca share price is telling. Over the past five years, the two have had a pretty similar overall result. Silence Therapeutics is up 77%, while AstraZeneca has the edge with a 92% gain. But that’s where the similarity ends.

A recent ten-bagger

AstraZeneca shares have been climbing steadily, while the Silence Therapeutics chart shows a history of boom and bust. Or perhaps bust and boom, as the price had been in a slump until the middle of 2019. But since then, Silence shares have soared more than tenfold in value, easily beating the AstraZeneca share price in the short term.

For the first half of the year, Silence Therapeutics recorded an £11m loss after tax. But it reported cash equivalents and term deposits of £50.3m at 30 June, which looks healthy. That’s an increase, and it’s driven by the firm’s collaboration with AstraZeneca. The firm received a cash payment of $60m and an equity investment of $20m, and stands to reap “up to $400 million in potential milestones for each target plus tiered royalties“.

AstraZeneca share price picking up

Speaking of AstraZeneca, the pharmaceuticals giant had just paused its late-stage Covid-19 study after a patient taking part reported a side effect. But the trial has already been resumed. The AstraZeneca share price hasn’t done much yet in response, but hopefully any renewed Covid-19 pessimism will have subsided a little.

Meanwhile, the AstraZeneca resurgence under boss Pascal Soriot continues. The company’s shares had been in the dumps due to the loss of patents and a drying up development pipeline. Big investment in research is reversing that situation, though it was always going to be a long-term project.

Not too late to buy

But with the AstraZeneca share price’s impressive performance of the past five years, have investors missed the boat? I’d say a big no to that.

Profits from the firm’s refocused research and development are really only just starting to come through. Forecasts suggest a price-to-earnings multiple for 2021 of a little over 20, and I reckon a few years of earnings growth could soon see that tumble. And that should feed through to higher dividend yields too, currently at around 2.6%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Should I invest in the FTSE 100 – or try to beat it?

Our writer has the option of investing in a FTSE 100 tracker fund. So why does he choose to buy…

Read more »

Young black woman walking in Central London for shopping
Investing Articles

£1,500 to invest in a Stocks and Shares ISA? Here’s how I’d do it

Our writer has been investing in his Stocks and Shares ISA. Here he details how he could put £1,500 in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

2 top FTSE 100 shares I’d buy before the market rebounds!

Christopher Ruane identifies a pair of FTSE 100 shares that have both tumbled in the past year and that he…

Read more »

Business development to success and FTSE 100 250 350 growth concept.
Investing Articles

Here’s why the next bull market may have already begun

The UK stock market has taken the Bank of England's interest rate hike in its stride and green shoots suggest…

Read more »

Gold medal
Investing Articles

No contest! Here’s my stock of the week

An update from this company offered some relief from the economic gloom. It's this Fool's stock of the week.

Read more »

Cogs turning against each other
Investing Articles

Scottish Mortgage shares are back on the rise: is now the time to jump onboard?

Scottish Mortgage shares have risen over 25% in the past 30 days. This Fool takes a look at why and…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Why do Lloyds shares seem so cheap?

Lloyds shares have been losing ground and now look cheap on some valuations. So why has our writer removed the…

Read more »

Investing Articles

How to invest in shares to help beat inflation

Soaring prices could well outstrip our investing returns this year. I think it's more important to find shares to beat…

Read more »